HOT NEWS
Boehringer Ingelheim launches 'Lean-to-Clinic' program for fast drug product sup... » Boehringer Ingelheim has expanded its biopharmaceutical cell line development services and provides ...
43 research talents awarded scholarships to help secure Denmark's future » 43 of Denmark's most talented students in the biotechnological and pharmaceutical sciences will toda...
Novartis drug Signifor® recommended by CHMP for EU approval » The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ado...
Genzyme Announces European Approval of Framingham Manufacturing Plant » Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that the European Me...
AstraZeneca and IMS Health announce real-world evidence collaboration in Europe » AstraZeneca has entered into a three-year collaboration agreement with IMS Health, the leading provi...
MyAsthma App - a New Dimension in Asthma Control » GlaxoSmithKline (GSK) has announced the launch of MyAsthma, the UK's first, free personalised health...
Shire's Venvanse® (lisdexamfetamine dimesylate) Marketing Application accepted ... » Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced...
Bayer's Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for Sec... » Bayer HealthCare has submitted an application for marketing authorization to the European Medicines ...
Avastin receives EU approval for the treatment of women with newly diagnosed, ad... » Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission has approved Avastin (beva...
First-of-its-Kind Endovascular Trial of the Investigational Esprit(TM) Therapy » Abbott (NYSE: ABT) today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in...
Nycomed
NycomedNycomed is a Takeda company since end of September 2011. Takeda is a research-based global company with its main focus on pharmaceuticals. The combined company has an active commercial presence in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.

Takeda's traditional strengths in North America, Japan, and the rest of Asia, are now complemented by Nycomed's position in Europe and the high growth emerging markets. The combined company has a presence in more than 70 countries worldwide, and ranked 12th by global Rx sales, 14th in the BRIC countries and 18th in Europe. For more information visit www.nycomed.com.

Nycomed RSS Channel
Title Filter     Display # 
# Article Title Hits
1 Takeda Appoints Jostein Davidsen Head of Emerging Markets 2683
2 Nycomed reports double-digit growth across emerging markets in second quarter 2011 3824
3 Nycomed continues to outperform in emerging markets in first quarter 2011 5096
4 Takeda to Acquire Nycomed - Transaction will Transform Takeda's Global Business 5227
5 Nycomed well positioned in emerging markets 6784
6 Nycomed Announces Agreement with Eurand for ZENPEP® in Russia-CIS 6535
7 Daxas® (Roflumilast) included as a new treatment option in latest international COPD guidelines 9658
8 Nycomed is keeping the pace in third quarter 2010 7411
9 Global market launch of Daxas® (Roflumilast) kicks off in Germany 9438
10 Nycomed's Daxas® (roflumilast) receives marketing authorisation in the European Union 9982
11 Nycomed's first quarter 2010 results confirm the direction 6261
12 Nycomed's novel anti-inflammatory therapy Daxas® (roflumilast) recommended for approval in the European Union 6553
13 Nycomed on track in 2009 with strong growth in Key Products 4607
14 Nycomed sustains commitment to Russia-CIS and invests in new pharmaceutical production plant 5326
15 Nycomed reports sustained momentum in second quarter 2009 3283
16 Nycomed to acquire local portfolio from Sanofi-Aventis and Zentiva 3702
17 Nycomed's Instanyl® is first intranasal fentanyl approved in Europe 5363
18 Nycomed receives Marketing Authorization for Pantoprazole 20mg OTC from European Commission 6308
19 Nycomed Reports a Solid Start to 2009 2138
20 Nycomed files European marketing authorisation application for Daxas® 2589
 
  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  Next 
  •  End 
  • »
Page 1 of 2
Bookmark and Share